| CDSS version 0.9 (n=1,176) | CDSS version 1.0 (n=1,333) |
---|---|---|
Group 1: HDF drug | 26.1% | 31.7% |
Group 2: Pharmaceutical equivalent | 45.2% | 40.7% |
Group 3: Pharmaceutical alternative | 14.0% | 12.2% |
Group 4: Therapeutic equivalent | 8.3% | 7.0% |
ÎŁ: CDSS-switch | 93.6%* | 91.6% |
Group 5: No CDSS-switch | 6.5%* | 8.4% |